Efficacy and Safety of AQX-1125 in IC/BPS (LEADERSHIP)
A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway
Sponsor: Aquinox Pharmaceuticals (Canada) Inc.
A PHASE2 clinical study on Bladder Pain Syndrome and Interstitial Cystitis, this trial is completed. The trial is conducted by Aquinox Pharmaceuticals (Canada) Inc. and has accumulated 9 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Oct 2017 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jun 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aquinox Pharmaceuticals (Canada) Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barrie, Canada , Brampton, Canada , Brantford, Canada , Burlington, Canada , Calgary, Canada , DeSoto, United States , Denver, United States , Farmington, United States , Garden City, United States , Glendora, United States and 18 more locations